Abstracts tagged "quality of life"

Abstract Number: 2122 • ACR Convergence 2022
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna Gladman¹, Lars Erik², Diamant Thaci³, Paolo Gisondi⁴, Laure Gossec⁵, M. Elaine Husni⁶, Alice Gottlieb⁷, Hiroaki Dobashi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and William Tillett¹², ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ³Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ⁴Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁵Sorbonne Université, Paris, France, ⁶Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
Abstract Number: 0412 • ACR Convergence 2022
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Lianne Gensler³, Jonathan Kay⁴, Victoria Navarro-Compán⁵, Christine de la Loge⁶, Alicia Ellis⁷, Carmen Fleurinck⁸, Marga Oortgiesen⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Colombes, France, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impacts patients' (pts) physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively…
Abstract Number: 1356 • ACR Convergence 2022
Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
Camille Mettler¹, Veronique Le Guern², Paul Legendre¹, Caroline Morbieu¹, Tali-Anne Swebel¹, Xavier Puéchal³, Pascal Cohen³, Hicham Kardaoui¹, Alexandre Moores¹, Luc Mouthon³, Nathalie Costedoat-Chalumeau⁴ and Benjamin Terrier³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, ²Hôpital Cochin, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Inserm DR Paris 5, Paris, France
Background/Purpose: Systemic autoimmune diseases (AID) are chronic conditions with significant burden related to the disease itself, its management, and treatments. Burden refers to the workload…
Abstract Number: 2173 • ACR Convergence 2022
Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
Yossra Suliman¹, Julia mumper², Gary Feldman³, M. Cameron Hay⁴ and Daniel Furst⁵, ¹Assiut University Hospital, Assiut, Egypt, ²Miami University, Miami, OH, ³Pacific Arthritis, Los Angeles, CA, ⁴Miami University (Ohio), Oxford, OH, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: In the era of emerging need to utilize remote technology-based health care services due to the COVID-19 pandemic, we wanted to evaluate patient satisfaction…
Abstract Number: 0437 • ACR Convergence 2022
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Carol Langford², Chao Zhang², Leonard Calabrese², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol McAlear⁶, Paul Monach⁷, Larry Moreland⁸, Christian Pagnoux⁹, Ulrich Specks¹⁰, Antoine Sreih¹¹, Kenneth J. Warrington¹⁰ and Peter Merkel¹², ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸University of Colorado, Denver, CO, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Bristol Myers Squibb, Philadelphia, PA, ¹²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neurologic involvement (NI) in ANCA-associated vasculitis (AAV) is common, occurring in approximately one-third of patients, and leads to significant and often chronic functional limitations…
Abstract Number: 1386 • ACR Convergence 2022
The Association of Depression with Executive Function Skills and Health-Related Quality of Life in Youth with Systemic Lupus Erythematosus
Busisiwe Zapparoli¹, Sarah Mossad¹, Stephanie Fevrier², Victoria Lishak³, Tala El Tal⁴, Lawrence Ng¹, Paris Moaf¹, Joanna Law¹, Ibrahim Mohamed⁵, Linda Hiraki⁶, Deborah Levy⁷, ashley Danguecan¹ and Andrea Knight⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁶The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression is a frequent symptom in childhood-onset SLE (cSLE), and is likely multifactorial. Executive function (EF) refers to conscious and volitional efforts to regulate…
Abstract Number: 2239 • ACR Convergence 2022
Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Rohit Aggarwal¹, Christina Charles-Schoeman², joachim Schessl³, Victoria Werth⁴, Zsuzsanna Bata-Csorgo⁵, Mazen Dimachkie⁶, Zoltan Griger⁷, Sergey Moiseev⁸, Chester Oddis⁹, Elena Schiopu¹⁰, Jiří Vencovský¹¹, Irene Beckmann¹², Elisabeth Clodi¹³, Todd Levine¹⁴ and and the ProDERM investigators¹⁵, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ³Friedrich-Baur-Institut/Medical University Munich, Mainkofen, Germany, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁶University of Kansas Medical Center, Kansas City, KS, ⁷University of Debrecen, Debrecen, Hungary, ⁸First Moscow State Medical University, Moscow, Russia, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹²Octapharma PharmazeutikaProduktionsGesmbH, Vienna, Austria, ¹³Octapharma Pharmazeutika ProduktionsgesmbH, Vienna, Austria, ¹⁴Phoenix Neurological Associates, Ltd., Phoenix, AZ, ¹⁵Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…
Abstract Number: 0441 • ACR Convergence 2022
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort
José Joel Hurtado-Arias¹, Isabela Ramírez-Mulhern², Javier Merayo-Chalico³, Carlos A. Gonzalez-Martinez⁴, Ana Barrera-Vargas² and Andrea Hinojosa-Azaola¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ⁴Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: The antineutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) are a group of complex chronic diseases resulting in morbidity, accumulated organ damage, treatment burden, and…
Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Eldon Jupe¹, Gerald Lushington², Mohan Purushothaman¹, Fabricio Pautasso¹, Georg Armstrong¹, Arif Sorathia¹, Jessica Crawley¹, Vijay Nadipelli³, Bernie Rubin⁴, Ryan Newhardt¹, Melissa Munroe¹ and Brett Adelman¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OR, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
Abstract Number: PP03 • ACR Convergence 2022
To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: In November 1999, the Institute of Medicine issued a press release announcing publication of To Err is Human: Building a Safer Health System (Kohn…
Abstract Number: 0444 • ACR Convergence 2022
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Cristina Burroughs³, Kalen Larson², Christine Yeung⁴, Peter Merkel⁵ and Robert Spiera⁶, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…
Abstract Number: PP04 • ACR Convergence 2022
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Kara Wada, The Ohio State University, Columbus, OH
Background/Purpose: After years of ignoring my dry eyes and mouth, unrelenting fatigue, and body pain, an off-the-cuff comment from my dental hygienist finally pushed me…
Abstract Number: 0729 • ACR Convergence 2022
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Y. Ingrid Goh¹, Esi Morgan², Meghan Ryan³, Beth Gottlieb⁴ and Nancy Pan⁵, ¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ²Seattle Children's Hospital, Seattle, WA, ³University of Minnesota, Vadnais Heights, MN, ⁴Cohen Children's Medical Center, Lake Success, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
Abstract Number: 1507 • ACR Convergence 2022
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
Neel Tapryal¹, George Gondo², M. Elaine Husni³, Alice Gottlieb⁴ and Joseph Merola⁵, ¹Cleveland Clinic, Rocky River, OH, ²National Psoriasis Foundation, Portland, OR, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis in which the time between symptom onset and a diagnosis of PsA is highly variable.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].